Dr. Roger J. Garceau M.D. serves as Chief Executive Officer, Director of the Company. Dr. Garceau is a seasoned pharmaceutical executive with more than 30 years of industry experience and has served as a Director of the Company since March 2016 and as Chief Development Advisor since December 2016. Prior to joining Entera, Dr. Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. (NPS), since December 2008 and January 2013 respectively, until February 2015, when NPS was acquired by Shire plc. Prior to his time at NPS, Dr. Garceau served in several managerial positions Sanofi-aventis and Pharmacia Corporation. Dr Garceau has been a non-executive director of Enterome SA since December 2016. He is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. Dr. Garceau holds B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School.
As the Chief Executive Officer a Director of Entera Bio Ltd, the total compensation of Roger Garceau at Entera Bio Ltd is $378,342. There are 4 executives at Entera Bio Ltd getting paid more, with Phillip Schwartz having the highest compensation of $722,014.
Roger Garceau is 66, he's been the Chief Executive Officer a Director of Entera Bio Ltd since 2020. There are 6 older and 12 younger executives at Entera Bio Ltd. The oldest executive at Entera Bio Ltd is Gerald Lieberman, 73, who is the Independent Chairman of the Board.
Roger's mailing address filed with the SEC is C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010.
Over the last 3 years, insiders at Entera Bio Ltd have traded over $0 worth of Entera Bio Ltd stock and bought 467,822 units worth $484,536 . The most active insiders traders include Gerald M Lieberman, Miranda Jayne Toledano a Sean Ellis. On average, Entera Bio Ltd executives and independent directors trade stock every 32 days with the average trade being worth of $36,205. The most recent stock trade was executed by Haya Taitel on 12 January 2024, trading 9,500 units of ENTX stock currently worth $9,405.
Entera Bio Ltd executives and other stock owners filed with the SEC include: